Ultradeep pyrosequencing and molecular modeling identify key structural features of hepatitis B virus RNase H, a putative target for antiviral intervention

Journal of Virology

Volumn 88, Issue 1, 2014, Pages 574-582

  Hayer, Juliette ^a   Rodriguez, Christophe ^b,c   Germanidis, Georgios ^d   Deléage, Gilbert ^a   Zoulim, Fabien ^e,f   Pawlotsky, Jean Michel ^b,c   Combet, Christophe ^a  

^a UNIVERSITÉ LYON 1   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c INSERM U955   (France)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^f HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEASE H;

ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CELL CYCLE; CONTROLLED STUDY; ENTROPY; ENZYME ACTIVITY; ENZYME STRUCTURE, FUNCTION AND VARIABILITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE D; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; ULTRADEEP PYROSEQUENCING; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; GENOTYPE; HEPATITIS B VIRUS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RIBONUCLEASE H; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84890868759     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03000-13     Document Type: Article

References (50)

1. Wei Y, Neuveut C, Tiollais P, Buendia MA. 2010. Molecular biology of the hepatitis B virus and role of the X gene. Pathol. Biol. (Paris) 58:267-272. http://dx.doi.org/10.1016/j.patbio.2010.03.005.
2. European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 57:167-185. http://dx.doi.org/10.1016/j.jhep.2012.02.010.
3. Wang GH, Seeger C. 1992. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71:663-670. http://dx.doi.org/10.1016/0092-8674(92)90599-8.
4. Locarnini S, Mason WS. 2006. Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 44:422-431. http://dx.doi.org/10.1016/j .jhep.2005.11.036.
5. Locarnini S. 2008. Primary resistance, multidrug resistance, and crossresistance pathways in HBV as a consequence of treatment failure. Hepatol. Int. 2:147-151. http://dx.doi.org/10.1007/s12072-008-9048-3.
6. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-608.e1-2. http://dx.doi.org/10 .1053/j.gastro.2009.08.063.
7. European Association for the Study of the Liver. 2009. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50: 227-242. http://dx.doi.org/10.1016/j.jhep.2008.10.001.
8. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F. 2008. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J. Hepatol. 48:747-755. http://dx.doi.org/10 .1016/j.jhep.2008.01.027.
9. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:73-80. http://dx .doi.org/10.1002/hep.23246.
10. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. 2011. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60:247-254. http://dx.doi.org/10.1136/gut.2010.223206.
11. Zoulim F. 2012. Are novel combination therapies needed for chronic hepatitis B? Antiviral Res. 96:256-259. http://dx.doi.org/10.1016/j .antiviral.2012.09.006.
12. Davies JF, Hostomska Z, Hostomsky Z, Jordan SR, Matthews DA. 1991. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 252:88-95. http://dx.doi.org/10.1126/science.1707186.
13. Ishikawa K, Okumura M, Katayanagi K, Kimura S, Kanaya S, Nakamura H, Morikawa K. 1993. Crystal structure of ribonuclease H from Thermus thermophilus HB8 refined at 2.8 A resolution. J. Mol. Biol. 230: 529-542. http://dx.doi.org/10.1006/jmbi.1993.1169.
14. Katayanagi K, Okumura M, Morikawa K. 1993. Crystal structure of Escherichia coli RNase HI in complex with Mg2 at 2.8 A resolution: proof for a single Mg(2 )-binding site. Proteins 17:337-346. http://dx .doi.org/10.1002/prot.340170402.
15. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. 2002. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. U. S. A. 99:14410-14415. http://dx.doi.org/10.1073/pnas.222366699.
16. Nowotny M, Gaidamakov SA, Crouch RJ, Yang W. 2005. Crystal structures of RNaseHbound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121:1005-1016. http://dx.doi.org/10.1016/j.cell.2005.04.024.
17. Lim D, Gregorio GG, Bingman C, Martinez-Hackert E, Hendrickson WA, Goff SP. 2006. Crystal structure of the Moloney murine leukemia virus RNaseHdomain. J. Virol. 80:8379-8389. http://dx.doi.org/10.1128/JVI.00750-06.
18. Nowotny M, Gaidamakov SA, Ghirlando R, Cerritelli SM, Crouch RJ, Yang W. 2007. Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol. Cell 28:264-276. http://dx.doi.org/10.1016/j.molcel.2007.08.015.
19. You DJ, Chon H, Koga Y, Takano K, Kanaya S. 2007. Crystal structure of type 1 ribonuclease H from hyperthermophilic archaeon Sulfolobus tokodaii: role of arginine 118 and C-terminal anchoring. Biochemistry 46:11494-11503. http://dx.doi.org/10.1021/bi700830f.
20. Kim HY, Kwon HD, Jang TS, Lim J, Lee HS. 2012. Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy. PLoS One 7:e50377. http://dx.doi.org/10.1371/journal.pone.0050377.
21. Leo B, Schweimer K, Rösch P, Hartl MJ, Wöhrl BM. 2012. The solution structure of the prototype foamy virus RNase H domain indicates an important role of the basic loop in substrate binding. Retrovirology 9:73. http://dx.doi.org/10.1186/1742-4690-9-73.
22. Cerritelli SM, Crouch RJ. 2009. Ribonuclease H: the enzymes in eukaryotes. FEBS J. 276:1494-1505. http://dx.doi.org/10.1111/j.1742-4658 .2009.06908.x.
23. Champoux JJ, Schultz SJ. 2009. Ribonuclease H: properties, substrate specificity and roles in retroviral reverse transcription. FEBS J. 276:1506-1516. http://dx.doi.org/10.1111/j.1742-4658.2009.06909.x.
24. Tadokoro T, Kanaya S. 2009. Ribonuclease H: molecular diversities, substrate binding domains, and catalytic mechanism of the prokaryotic enzymes. FEBS J. 276:1482-1493. http://dx.doi.org/10.1111/j.1742-4658 .2009.06907.x.
25. Kanaya S, Katayanagi K, Morikawa K, Inoue H, Ohtsuka E, Ikehara M. 1991. Effect of mutagenesis at each of five histidine residues on enzymatic activity and stability of ribonuclease H from Escherichia coli. Eur. J. Biochem. 198:437-440. http://dx.doi.org/10.1111/j.1432-1033.1991 .tb16033.x.
26. Potenza N, Salvatore V, Raimondo D, Falanga D, Nobile V, Peterson DL, Russo A. 2007. Optimized expression from a synthetic gene of an untagged RNase H domain of human hepatitis B virus polymerase which is enzymatically active. Protein Expr. Purif. 55:93-99. http://dx.doi.org/10 .1016/j.pep.2007.04.005.
27. Kabsch W, Sander C. 1983. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22:2577-2637. http://dx.doi.org/10.1002/bip.360221211.
28. Rost B, Sander C. 1993. Prediction of protein secondary structure at better than 70% accuracy. J. Mol. Biol. 232:584-599. http://dx.doi.org/10 .1006/jmbi.1993.1413.
29. King RD, Sternberg MJ. 1996. Identification and application of the concepts important for accurate and reliable protein secondary structure prediction. Protein Sci. 5:2298-2310. http://dx.doi.org/10.1002/pro .5560051116.
30. Geourjon C, Deléage G. 1995. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Comput. Appl. Biosci. 11:681-684.
31. Combet C, Blanchet C, Geourjon C, Deléage G. 2000. NPS@: network protein sequence analysis. Trends Biochem. Sci. 25:147-150. http://dx.doi .org/10.1016/S0968-0004(99)01540-6.
32. Combet C, Jambon M, Deléage G, Geourjon C. 2002. Geno3D: automatic comparative molecular modelling of protein. Bioinformatics 18: 213-214. http://dx.doi.org/10.1093/bioinformatics/18.1.213.
33. Brunger AT. 2007. Version 1.2 of the Crystallography and NMR system. Nat. Protoc. 2:2728-2733. http://dx.doi.org/10.1038/nprot.2007.406.
34. Hayer J, Jadeau F, Deléage G, Kay A, Zoulim F, Combet C. 2013. HBVdb: a knowledge database for hepatitis B virus. Nucleic Acids Res. 41:D566-D570. http://dx.doi.org/10.1093/nar/gks1022.
35. Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky JM. 2013. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology 58:890-901. http://dx.doi.org/10 .1002/hep.26383.
36. Rodriguez C, Chevaliez S, Pawlotsky JM. September 2010. PyroClass. French patent IDDN.FR. 001.360005.001.S.P. 2010.000.31230.
37. Rodriguez C, Chevaliez S, Pawlotsky JM. September 2010. PyroMute. French patent IDDN.FR. 001.120008.001.S.C. 2010.000.31230.
38. Rodriguez C, Chevaliez S, Pawlotsky JM. September 2010. PyroDyn. French patent IDDN.FR. 001.370024.000.S.P. 2010.000.31230.
39. Laskowski RA, Rullmann JA, MacArthur MW, Kaptein R, Thornton JM. 1996. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8:477-486. http://dx.doi.org/10.1007/BF00228148.
40. Chang LJ, Hirsch RC, Ganem D, Varmus HE. 1990. Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J. Virol. 64:5553-5558.
41. Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen EJ, Parniak MA, Sarafianos SG. 2013. The hepatitis B virus ribonucleaseHis sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog. 9:e1003125. http://dx.doi.org/10.1371/journal.ppat.1003125.
42. Oda Y, Yoshida M, Kanaya S. 1993. Role of histidine 124 in the catalytic function of ribonuclease HI from Escherichia coli. J. Biol. Chem. 268:88-92.
43. Ho MH, De Vivo M, Dal Peraro M, Klein ML. 2010. Understanding the effect of magnesium ion concentration on the catalytic activity of ribonuclease H through computation: does a third metal binding site modulate endonuclease catalysis?. J. Am. Chem. Soc. 132:13702-13712. http://dx.doi .org/10.1021/ja102933y.
44. Nakamura H, Oda Y, Iwai S, Inoue H, Ohtsuka E, Kanaya S, Kimura S, Katsuda C, Katayanagi K, Morikawa K. 1991. How does RNase H recognize a DNA.RNA hybrid? Proc. Natl. Acad. Sci. U. S. A. 88:11535-11539. http://dx.doi.org/10.1073/pnas.88.24.11535.
45. Lener D, Budihas SR, Le Grice SF. 2002. Mutating conserved residues in the ribonuclease H domain of Ty3 reverse transcriptase affects specialized cleavage events. J. Biol. Chem. 277:26486-26495. http://dx.doi.org/10 .1074/jbc.M200496200.
46. Yang W, Hendrickson WA, Crouch RJ, Satow Y. 1990. Structure of ribonucleaseHphased at 2 A resolution byMADanalysis of the selenomethionyl protein. Science 249:1398-1405. http://dx.doi.org/10.1126/science.2169648.
47. Kashiwagi T, Jeanteur D, Haruki M, Katayanagi K, Kanaya S, Morikawa K. 1996. Proposal for new catalytic roles for two invariant residues in Escherichia coli ribonuclease HI. Protein Eng. 9:857-867. http://dx.doi .org/10.1093/protein/9.10.857.
48. Campbell AG. 2001. Expression of Moloney murine leukemia virus RNase H rescues the growth defect of an Escherichia coli mutant. J. Virol. 75:6212-6217. http://dx.doi.org/10.1128/JVI.75.13.6212-6217.2001.
49. Gong Y, Yao E, Tavis JE. 2001. Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates. BMC Microbiol. 1:12. http://dx.doi.org/10.1186/1471-2180-1-12.
50. Gouet P. 2003. ESPript/ENDscript: extracting and rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res. 31:3320-3323. http://dx.doi.org/10.1093/nar/gkg556.